Skip to main content

Varying and "atypical" indications for atypical antipsychotics

This is a preview of subscription content, access via your institution.

References

  • Barbui C, Guaiana G, Garattini S (2001) Regulatory issues in Europe. J Clin Psychopharmacol 21:545–548

    Article  CAS  PubMed  Google Scholar 

  • Garattini S, Bertelé V (2001) Adjusting Europe's drug regulation to public health needs. Lancet 358:64–67

    Article  CAS  PubMed  Google Scholar 

  • Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376

    CAS  PubMed  Google Scholar 

  • Kerwin RW (1994) The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry 164:141–148

    CAS  PubMed  Google Scholar 

  • Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker WW (2000) Off-label use of antipsychotic drugs. J Clin Psychopharmacol 20:695–698

    Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Corrado Barbui.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Barbui, C., Tansella, M. & Garattini, S. Varying and "atypical" indications for atypical antipsychotics. Psychopharmacology 169, 205–206 (2003). https://doi.org/10.1007/s00213-003-1495-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-003-1495-x

Keywords

  • Schizophrenia
  • Clozapine
  • Risperidone
  • Olanzapine
  • Quetiapine